ArticleJACC. Advances2024
Comparison of Physical Frailty Assessments in Heart Failure With Preserved Ejection Fraction.
Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial.Cardiovascular diabetology · 2025Trial
- Frailty and Echocardiographic Indices of Diastolic Function in Older Adults: A Cross-Sectional Analysis.Journal of clinical medicine · 2026Article
- Life-Space Mobility in Heart Failure With Preserved Ejection Fraction.Journal of cardiac failure - intersections · 2026Article
- Early albumin infusion and mortality in ICU patients with HFpEF: a target trial emulation study.European journal of clinical pharmacology · 2026Article
- Strengths and limitations of HFpEF probability scores in the era of precision medicine.Frontiers in medicine · 2026Review
- Frailty as an independent predictor of one-year outcomes in patients with HFpEF after acute myocardial infarction: insights from a multicenter retrospective cohort in China.Journal of geriatric cardiology : JGC · 2025Article
- Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update.Journal of cachexia, sarcopenia and muscle · 2025Article
- Frailty Among Patients With ADPKD.Kidney international reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Frailty is a known determinant of poor clinical outcomes in heart failure with preserved ejection fraction (HFpEF). However, prevalence estimates and effect sizes vary in part due to multiple tools available to measure frailty. Objectives: This study aimed to compare the prevalence and prognostic value of six commonly used frailty assessments in adults with HFpEF. Methods: We examined 203 outpatients with HFpEF seen at Weill Cornell Medicine from June 2018 to August 2022. The following frailty scales were compared: the Clinical Frailty Scale (CFS), the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight scale (FRAIL) scale, the 5-m gait speed test, the 5 timed sit-to-stand test, hypoalbuminemia, and the modified body mass index score. The primary endpoint was a 1-year composite of all-cause mortality and hospitalization. Cox proportional hazard models were used to examine the association between frailty and the primary endpoint, adjusting for race and the MAGGIC (Meta-Analysis Global Group in Chronic) heart failure prognostic risk score. Results: The median age was 76.7 years (IQR: 69.7-83.9 years). The prevalence of frailty ranged from 21.2% (hypoalbuminemia) to 77.8% (5 timed sit-to-stand) and increased with advancing HFpEF severity. Of the 6 frailty assessments, the CFS (HR: 2.83; 95% CI: 1.61-4.98, Conclusions: Frailty assessments yield a wide range of prevalence estimates and vary in their associations with clinical outcomes. The CFS, FRAIL scale, and the 5-m gait speed tests demonstrated associations with adverse outcomes and may thus be reasonable tools for routine use in patients with HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.